Running a US Startup from China: A Founder's Tax Guide (2026)

If you're a founder in China building a company for the US market, you've probably already done the obvious thing: incorporated a Delaware C-corp so you can raise from US investors. What most guides skip is the tax stack that comes with being a foreign founder of a US company — a stack that's different from, and heavier than, what a US-based founder deals with. This is the field guide.

The good news: most of it is standard US tax law that applies to your company the same as anyone's. The traps are in three specific places — foreign-ownership reporting, a foreign team, and moving capital across the border.

Your Delaware C-corp is a US taxpayer — that part is normal

The corporation files Form 1120 and pays US corporate tax on its income regardless of where you live. QSBS, the R&D credit, Delaware franchise tax, multi-state nexus — all of it applies to your company exactly as it would for a US founder. So the work we cover in our first-year checklist, Delaware franchise tax, and multi-state nexus guides is the same for you.

What's added by being a foreign founder lives below.

Trap 1: Form 5472 (foreign-ownership reporting)

If you (a non-US person) own 25% or more of your US corporation, the company must file Form 5472 to report "reportable transactions" with foreign related parties — your capital contributions, any loans, any payments between you/your foreign entities and the US company. It's filed with the 1120.

This is the single most-missed filing for China-based founders, and the penalty is $25,000 per form. Foreign-owned US entities are a known IRS enforcement focus. If you funded your US company from China, you almost certainly have 5472 transactions to report.

Trap 2: your China engineering team is "foreign R&D"

This is where the US tax code quietly punishes the most common China-US setup — US entity, engineering in China.

Under §174A (2026), domestic R&D is fully deductible in the year incurred, but foreign research must be capitalized over 15 years (with a half-year convention, so year one deducts only 1/30). A China-based engineering team is foreign R&D. So most of what you pay that team is not deductible this year — it creates phantom taxable income.

See exactly what your domestic-vs-foreign split costs:

The full mechanics, and the 2022-2024 transition rules, are in our Section 174 guide. For a China-team-heavy startup this is often the largest single tax item — model it before filing, not after.

Trap 3: moving capital, and paying the team

Two operational questions that are mostly advisor territory — flagged here, not answered, because the specifics depend on facts and on rules that sit on the China side:

• Paying your China team or contractors. US tax treatment turns on where the work is performed and the worker's status, and it interacts with the US-China tax treaty. Services performed outside the US are generally not US-source (often no US withholding); US-performed services can trigger withholding and Form 1042-S.
• Getting money from China into the US company. This is governed by China's foreign-exchange rules, not US tax — SAFE registration, outbound-investment (ODI) approval, and anti-round-tripping rules (e.g. Circular 37) can apply. Holding structures (Cayman/Delaware holdco, WFOE, VIE) are sometimes used to manage it.

These two are exactly where a generic startup-accounting service leaves you on your own — and where a cross-border-aware firm earns its keep.

What still works in your favor (US side)

• QSBS (§1202) and the 83(b) election are features of US C-corp stock, not of your nationality. A founder in China holding qualifying Delaware stock can file an 83(b) within 30 days of grant and target the QSBS exclusion at exit — on the US side. (China's treatment of the same gain is a separate question.) See our 83(b) and QSBS guides.
• The R&D credit (§41) can still offset payroll tax for a qualified small business — but remember it's computed on US-qualified research, so a China engineering team's wages generally don't count toward it. See the R&D credit guide.

What's standardized vs. what's advisor-only

Be clear-eyed about which parts are productizable and which aren't:

• Standardized (we do this): the US-side stack — 1120 + 5472, bookkeeping, §174 treatment, R&D credit, Delaware franchise, multi-state.
• Advisor / referral (not a standard product): China-side forex (SAFE/ODI), VIE or holdco structuring, China personal tax, and treaty-position opinions. These need China counsel and a cross-border CPA; treat anyone selling them as a flat "product" with suspicion.

Bottom line

A Delaware C-corp run from China is mostly a normal US tax filing with three extra weights bolted on: Form 5472, the §174 foreign-R&D drag on your China team, and the cross-border capital and payroll questions. Get the first two handled as standard US work, and get specific cross-border advice on the third — don't let a generic accountant tell you it's all the same as a US founder, and don't let anyone sell you a one-size structure without looking at your facts.

This guide is informational only and is not tax or legal advice. US-side sources: Form 5472 instructions (IRS) · IRC §174A (OBBBA) · IRC §1202 / §83(b). China-side rules (SAFE registration, Circular 37, ODI) are summarized for orientation only; confirm specifics with cross-border counsel before acting.